Precision Medicine in Liver Dysfunction
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".
Deadline for manuscript submissions: closed (10 December 2023) | Viewed by 306
Special Issue Editor
Special Issue Information
Dear Colleagues,
Liver diseases have classically been associated with a high burden of comorbidity and mortality and constitute a persistent challenge for clinicians. Many agents can interfere with the proper functioning of the liver and include infectious toxic agents or even form part of the metabolic syndrome. The therapeutic advances in recent years have offered the possibility of curing one of the main etiological agents of liver disease, such as the hepatitis C virus (HCV), and have the cure of chronic hepatitis B (HBV) as their target. However, as long-term HCV and HBV suppression does not prevent hepatocellular carcinoma (HCC), prevention is another challenge. Liver toxicity, not only associated with alcohol consumption but also pharmacological in an increasingly aging population with polypharmacy, is a challenge, not only from the point of view of individualized clinical management but also as an anticipation and prevention strategy. Finally, we face a world population with 25–30% of citizens suffering from non-alcoholic fatty liver disease (NAFLD), majorly associated with methanolic dysfunction (MAFLD). Nowadays, this disease has become the principal factor for liver dysfunction and is associated with lower survival associated with inflammation and fibrosis earlier and more quickly. We are facing a therapeutic challenge where health education plays a fundamental role among patients and where, at the moment, we do not have sufficiently effective drugs to be implemented.
Dr. Jesús Troya
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HCV
- HBV
- NAFLD
- MAFLD
- hepatocarcinoma
